Compugen Ltd (NASDAQ:CGEN)
| 5.40 Data as of May 24 |  -0.04 / -0.74%Today’s Change | 2.96 Today|||52-Week Range 6.32 | +9.76% Year-to-Date |
Latest CGEN News | Press Releases
No recent news for Compugen Ltd.
Today’s Trading
| Previous close | 5.44 |
| Today’s open | 5.42 |
| Day’s range | 5.32 - 5.50 |
| Volume | 73,913 |
| Average volume (3 months) | 146,673 |
| Market cap | $199.0M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/24/2013
Growth & Valuation
| Earnings growth (last year) | -8.57% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | 728.74 |
| Price/Book | 11.26 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VSTMVerastem Inc | +0.03 | +0.32% |
| OVASOvaScience Inc | +0.10 | +0.87% |
| SIGASIGA Technologies In... | +0.06 | +1.67% |
| PSTIPluristem Therapeuti... | -0.03 | -0.98% |
Data as of 4:00pm ET, 05/24/2013
Financials
| Last reporting date | February 7, 2012 |
| EPS forecast (this quarter) | -$0.03 |
| Annual revenue (last year) | $242.0K |
| Annual profit (last year) | -$13.6M |
| Net profit margin | -5,631.40% |
Profile
Sector Health Technology |
Industry Biotechnology |
President & Chief Executive Officer Anat Cohen-Dayag, PhD |
Chief Financial Officer & Head-Investor Relations Dikla Czaczkes Axselbrad, MBA, CPA |
Corporate headquarters Tel Aviv, -- |
Forecasts
